Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Hookipa Pharma Inc
(NQ:
HOOK
)
0.9100
+0.0100 (+1.11%)
Streaming Delayed Price
Updated: 10:03 AM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Hookipa Pharma Inc
< Previous
1
2
Next >
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
April 26, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
April 25, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 24, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
April 10, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 22, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
March 06, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
January 29, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
January 16, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
December 21, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
November 20, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
November 03, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
November 02, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
October 22, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
October 18, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Announces Executive Leadership Change
September 13, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to participate in upcoming investor conferences in September
September 06, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 10, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
August 03, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
May 31, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
May 31, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 11, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
May 09, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
May 04, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023
May 04, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
April 26, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference
April 19, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.